Limertinib

利厄替尼

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameLimertinib
Drug Alias Name奥壹新ASK-120067ASK120067
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitors
TargetsEGFR T790M
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2025/01/14
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of SciencesJiangsu Aosaikang Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Aosaikang Pharmaceutical Co Ltd
Inactive CompaniesGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of SciencesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A